Has your doctor suggested nasal irrigation for seasonal allergy relief? Mine has, and nasal irrigation has become a very ...
The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals regarding the New Drug Application (NDA) for ...
Early diagnosis of COPD, chronic obstructive pulmonary disease, increases the quality of life of the patient and the efficacy ...
Stocktwits on MSN2d
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s PositiveShares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...
Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...
Milestone Pharmaceuticals said on Friday that the U.S. health regulator had declined to approve its nasal spray to treat a ...
Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...
The proposed overhaul of the U.S. Department of Health and Human Services could weaken and possibly eliminate a little-known ...
Milestone Pharmaceuticals had $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024.
The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.
Milestone Pharmaceuticals (MIST) announced the U.S. Food and Drug Administration, FDA, issued a Complete Response Letter, CRL, regarding its ...
Afrin and Flonase are over-the-counter nasal sprays. Learn how they compare in effectiveness, side effects, and safety to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback